Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

BACKGROUND: Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Diabetol
Hlavní autoři: Real, Jordi, Vlacho, Bogdan, Ortega, Emilio, Vallés, Joan Antoni, Mata-Cases, Manel, Castelblanco, Esmeralda, Wittbrodt, Eric T., Fenici, Peter, Kosiborod, Mikhail, Mauricio, Dídac, Franch-Nadal, Josep
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8272340/
https://ncbi.nlm.nih.gov/pubmed/34243779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01323-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky